Analyst consensus rating
Protara Therapeutics Analyst Rating: none
Direct answer
Protara Therapeutics's consensus rating is none.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.71.
Forecast evidence checked September 7, 2026.
Get free Protara Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.94
- Average price target
- $25.71
- High price target
- $30.00
- Low price target
- $20.00
- Low target gap
- +407.6%
- Target upside
- +552.6%
- High target gap
- +661.4%
- Target range width
- 253.8%
- Consensus rating
- none
- Analysts
- 7
- Evidence date
- September 7, 2026
- Valid through
- September 14, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Protara Therapeutics?
Protara Therapeutics has a verified none consensus. The same dataset has an average price target of $25.71.
How far are Protara Therapeutics's low and high targets from the recorded price?
The low target implies +407.6%, while the high target implies +661.4%.
How many analysts are included in Protara Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is Protara Therapeutics's target upside or downside calculated?
The average target of $25.71 is divided by the recorded price of $3.94, then one is subtracted to produce +552.6%. This does not guarantee a future return.
When was Protara Therapeutics's analyst forecast verified?
The data was verified on 2026-09-07. The dataset is valid through 2026-09-14.